Science 37 SPAC

Science 37 Investment Highlights. Disrupting the $60b Clinical Trial Industry Science 37 $3 § X X 1 ■ ■ ■ Category-Defining Clinical Trial Operating System Unifying technology platform to enable workflow, evidence generation and data harmonization On-demand telemedicine investigators and gig-economy nursing for home visits Integrations into networks (EHR and EDC) and connected devices to expedite trial operations Strong Financial Performance $444M net bookings in 2025 expected to increase from $119M in 2021 $362M revenue in 2025 expected to increase from $52M in 2021 Gross profit margin expected to increase to 55% in 2025 I I ■ ■ ■ ■ Significant Growth Opportunities Ahead Model expansion: commercial, geographic, technology Expanded offerings: rapidly growing adjacencies Potential M&A opportunities Up to 15x faster than traditional clinical trials Up to 28x greater patient/participant retention Up to 3x more diverse participants ■ 12

View entire presentation